Home » Authors » Brady Huggett

Articles by Brady Huggett

Aderis Postpones IPO; Market Seen As 'Discerning' This Time

Oct. 30, 2003

By Brady Huggett

Aderis Postpones IPO; Market Seen As 'Discerning' This Time

Oct. 30, 2003

By Brady Huggett

CytRx Farms Out Flocor To SynthRx, Focuses On RNAi

Oct. 24, 2003

By Brady Huggett

CytRx Farms Out Flocor To SynthRx, Focuses On RNAi

Oct. 24, 2003

By Brady Huggett

Durect Stock Falls 35 Percent On Likely Phase III Trial Delay

Oct. 20, 2003

By Brady Huggett

Durect Stock Falls 35 Percent On Likely Phase III Trial Delay

Oct. 20, 2003

By Brady Huggett

'On Track' Genentech Beats Street With Positive Earnings

Oct. 10, 2003

By Brady Huggett

'On Track' Genentech Beats Street With Positive Earnings

Oct. 10, 2003

By Brady Huggett

Biogen Licenses Psoriasis Product From Fumapharm

Oct. 2, 2003

By Brady Huggett

Biogen Licenses Psoriasis Product From Fumapharm

Oct. 2, 2003

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...